In summary, our findings suggest that patients treated with clopidogrel based on POC CYP2C19 genotyping experience a lower risk of MACE, including myocardial infarction, stroke, stent thrombosis, and death, as well as reduced recurrent MI. This evidence concerns the gene CYP2C19 and Stroke.